Actinium Pharmaceuticals, Inc. (ATNM) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ATNM Revenue Growth
Revenue Breakdown (FY 2023)
ATNM's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
ATNM Revenue Analysis (2013–2024)
As of May 8, 2026, Actinium Pharmaceuticals, Inc. (ATNM) generated trailing twelve-month (TTM) revenue of $90,000. The most recent quarter (Q3 2025) recorded $90,000 in revenue.
Looking at the longer-term picture, ATNM's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $1.1 million in 2021.
Revenue diversification analysis shows ATNM's business is primarily driven by Other Revenue Member (100%). With over half of revenue concentrated in Other Revenue Member, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RNAC (-94.8% YoY), PHAT (+150.3% YoY), and NVX (+24.0% YoY). Compare ATNM vs RNAC →
ATNM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ATNMCurrent | $90,000 | - | - | - | |
 RNAC | $3M | -94.8% | -30.0% | -3099.9% | |
 PHAT | $175M | +150.3% | - | -91.4% | |
 NVX | $6M | +24.0% | +6.6% | -880.0% | |
 RNW | $97.1B | +50.5% | +14.9% | 53.5% |
ATNM Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $-811,000 | - | $-42,121,000 | - |
| 2023 | $81K | -92.1% | $81K | 100.0% | $-51,920,000 | -64098.8% |
| 2022 | $1.0M | -10.0% | $1.0M | 100.0% | $-34,104,000 | -3311.1% |
| 2021 | $1.1M | - | $620K | 54.2% | $-24,964,000 | -2182.2% |
| 2020 | $0 | - | $-447,000 | - | $-22,393,000 | - |
| 2019 | $0 | - | $-420,089 | - | $-22,071,447 | - |
| 2018 | $0 | - | $-50,721 | - | $-23,827,000 | - |
| 2017 | $0 | - | $-55,938 | - | $-26,911,000 | - |
| 2016 | $0 | - | $-77,523 | - | $-26,847,000 | - |
| 2015 | $0 | - | $-53,465 | - | $-24,830,000 | - |
See ATNM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATNM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATNM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATNM — Frequently Asked Questions
Quick answers to the most common questions about buying ATNM stock.
Is ATNM's revenue growth accelerating or slowing?
ATNM TTM revenue: $90000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ATNM's long-term revenue growth rate?
Actinium Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ATNM's revenue distributed by segment?
ATNM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.